Posted by Michael Wonder on 24 Jan 2022
Health Canada approves Ipsen’s Sohonos (palovarotene) as the first approved treatment for fibrodysplasia ossificans progressiva
24 January 2022 - Ipsen today announced the Health Canada approval of Sohonos (palovarotene), an oral selective retinoic-acid receptor gamma agonist indicated to reduce the formation of heterotopic ossification (new bone formation) in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva.
Sohonos is approved for the treatment of patients with fibrodysplasia ossificans progressiva for both chronic use, and for flare-ups, in these patient populations.
This decision marks the first approval for Sohonos worldwide.
